So with the new press release putting phase three into question, what does this mean for the robotics company which was suppossed to aid in the TRC commercialization?
Tell me about it, and what about this as well?
May 8th, 2007 "InterCytex has signed a licensing agreement with BioLife Solutions Inc (a US based company), a leading developer and marketer of proprietary hypothermic storage and cryopreservation media products for cells and tissues.
Terms of the 10-year agreement include an intellectual property escrow provision which guarantees Intercytex access under certain conditions to BioLife’s HypoThermosol storage and preservation media when used in the production of Intercytex’ VAVELTA (ICX-RHY), a facial rejuvenation product and ICX-TRC, their hair regeneration product, as well as annual license fees payable to BioLife.
"
.